You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Vaxart Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Vaxart Company Info
News & Analysis
Vaxart is still in the coronavirus vaccine race, even though its competitors remain very far ahead.
Learn about the companies that are manufacturing COVID-19 vaccines and what you should know before investing in coronavirus vaccine stocks.
These players may change the world of medicine.
The company still is far from the vaccine race finish line.
The similarities are striking.
These stocks are all about cutting-edge technology.
The past 12 months have been difficult for the biotech stock.
Vaxart is winning in two crucial areas.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.